Nav: Home

Prospect of a new treatment for rheumatoid arthritis

August 23, 2018

An international research group led by Charité - Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis. The drug is effective in patients with moderate to severe forms of the disease who have shown an inadequate response to conventional disease modifying drugs. Results from this research have been published in The Lancet*.

Rheumatoid arthritis is a painful inflammatory condition affecting the joints and tendons, which is typically characterized by periods of increased disease activity. Prof. Dr. Gerd-Rüdiger Burmester, Head of Charité's Medical Department, Division of Rheumatology and Clinical Immunology, conducted a study to assess the efficacy of upadacitinib in patients with an inadequate response to 'conventional synthetic disease-modifying antirheumatic drugs'. Upadacitinib is a selective inhibitor of the enzyme Janus kinase 1 (JAK1) and has been shown to be efficacious in this patient group in earlier phase II clinical trials. By inhibiting JAK1, upadacitinib disrupts an important signaling pathway that is responsible for triggering inflammatory responses.

In the phase III study presented, patients treated with upadacitinib showed significant improvements in joint swelling when compared to patients receiving placebo. Patients also experienced less pain and showed improvements in joint function. Prof. Burmester is very pleased to see this new tablet-based treatment produce such significant improvements in clinical symptoms. "Our results prove that JAK inhibitors represent an effective treatment alternative in patients with long-term conditions who do not respond adequately to conventional drugs, and in those for whom biologics are not a good treatment option. JAK inhibitors could help these patients achieve a quick response to treatment, allowing them to gain control over their illness. The trial sponsor AbbVie is currently in the process of collating all trial results and submitting them to the European and US regulatory authorities for review."
-end-
*Burmester GR, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2018 Jun 23;391(10139):2503-2512. DOI: 10.1016/S0140-6736(18)31115-2.

Contact:

Prof. Dr. Gerd-Rüdiger Burmester
Head of the Department of Rheumatology and Clinical Immunology
Charité - Universitätsmedizin Berlin
Tel: +49 30 450 513 061
Email: gerd.burmester@charite.de

Links:

- Department of Rheumatology and Clinical Immunology

https://rheumatologie.charite.de/

- Original article in The Lancet (abstract)

https://www.sciencedirect.com/science/article/pii/S0140673618311152?via%3Dihub

Charité - Universitätsmedizin Berlin

Related Rheumatoid Arthritis Articles:

Rheumatoid arthritis -- can its onset be delayed or prevented?
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that leads to significant health issues as well as high treatment costs.
Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.
Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.
Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.
How environmental pollutants and genetics work together in rheumatoid arthritis
New research documents how chemicals and a certain gene activate an enzyme to increase the risk and severity of RA and bone destruction.
Rheumatoid arthritis meets precision medicine
Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study.
Causes of death in rheumatoid arthritis patients
Mortality rates were increased for patients with rheumatoid arthritis relative to the general population across all causes of death in a recent Arthritis Care & Research analysis.
Menopause found to worsen symptoms of rheumatoid arthritis
A recent study published in Rheumatology suggests that women with rheumatoid arthritis suffer a greater decline in physical function following menopause.
Jawbone loss predates rheumatoid arthritis
Jawbone loss caused by periodontitis predates the onset of rheumatoid arthritis.
Gel to fight rheumatoid arthritis
IBS scientists developed a potentially therapeutic gel, which detects nitric oxide, absorbs excess fluids and delivers drugs.
More Rheumatoid Arthritis News and Rheumatoid Arthritis Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Risk
Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#540 Specialize? Or Generalize?
Ever been called a "jack of all trades, master of none"? The world loves to elevate specialists, people who drill deep into a single topic. Those people are great. But there's a place for generalists too, argues David Epstein. Jacks of all trades are often more successful than specialists. And he's got science to back it up. We talk with Epstein about his latest book, "Range: Why Generalists Triumph in a Specialized World".
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.